World Health Organization2024-09-292024-09-292024-09-299789240100299 (electronic version)9789240100305 (print version)https://iris.who.int/handle/10665/379063v, 31 p.enCC BY-NC-SA 3.0 IGOhttps://creativecommons.org/licenses/by-nc-sa/3.0/igoHIV InfectionsAnti-HIV AgentsAntiviral AgentsAnti-Retroviral AgentsHIV Protease InhibitorDrug ResistanceDrug-Related Side Effects and Adverse ReactionsEvidence GapsTenofovirDarunavirRitonavirDosage FormsMeeting AbstractOptimization of second-line and third-line antiretroviral therapy for people living with HIV: meeting report, 27-28 November 2023Publicationsepidemiologydrug therapytherapeutic usestatistics and numerical dataWorld Health Organization